Tiziana Life Sciences Ltd., a clinical-stage biotechnology company, entered an agreement with Renaissance Lakewood LLC, a CDMO, to advance the development intra-nasal drug candidate Foralumab.

Foralumab, a biologic drug candidate, is Tiziana’s fully human anti-CD3 monoclonal antibody in development for neurodegenerative and inflammatory diseases.

Under the agreement, Renaissance will use its expertise in nasal drug delivery to optimize the formulation of intranasal Foralumab and assist with scaling up production for clinical trials.
Tiziana is working to expediting the clinical development of Foralumab, particularly for conditions like Alzheimer’s disease and multiple sclerosis, where neuroinflammation plays a significant role in disease progression.

Intranasal foralumab has shown promising potential in early clinical studies, including significant improvements in immune modulation by activating T regulatory cells that cross the blood-brain barrier, offering a novel treatment approach for neuroinflammatory and neurodegenerative diseases.